MCID: LMN015
MIFTS: 34

Luminal Breast Carcinoma a

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma a

MalaCards integrated aliases for Luminal Breast Carcinoma a:

Name: Luminal Breast Carcinoma a 12 15
Breast Tumor Luminal 12 17
Luminal a Breast Carcinoma 12
Luminal Breast Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548
NCIt 50 C53554
UMLS 70 C3642345

Summaries for Luminal Breast Carcinoma a

Disease Ontology : 12 A breast carcinoma that is characterized by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.

MalaCards based summary : Luminal Breast Carcinoma a, also known as breast tumor luminal, is related to breast cancer and estrogen-receptor positive breast cancer. An important gene associated with Luminal Breast Carcinoma a is ASF1B (Anti-Silencing Function 1B Histone Chaperone), and among its related pathways/superpathways are Chromosome Maintenance and Chromatin Regulation / Acetylation. The drugs Vitamin D and Calciferol have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Luminal Breast Carcinoma a

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma a:



Diseases related to Luminal Breast Carcinoma a

Symptoms & Phenotypes for Luminal Breast Carcinoma a

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.68 ASF1B MBD6
2 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.68 MBD6
3 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.68 MBD6
4 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.68 MBD6
5 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.68 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.68 ERBB2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-171 9.68 ASF1B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.68 ASF1B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.68 MBD6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.68 MBD6
11 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.68 ERBB2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.68 MBD6
13 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.68 ASF1B ERBB2 MBD6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.68 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-62 9.68 ASF1B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.68 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.68 ASF1B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.68 ERBB2 MBD6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.68 ERBB2
20 Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression GR00224-A-2 8.96 MED11 MED7

Drugs & Therapeutics for Luminal Breast Carcinoma a

Drugs for Luminal Breast Carcinoma a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
2 Calciferol Phase 4
3 Calcium, Dietary Phase 4
4
Calcium Nutraceutical Phase 4 7440-70-2 271
5
Palbociclib Approved, Investigational Phase 3 571190-30-2 5005498 5330286 11431660
6
Goserelin Approved Phase 3 65807-02-5 47725 5311128
7
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
8 Hormone Antagonists Phase 3
9 Hormones Phase 3
10 Estrogens Phase 3
11 Estrogen Receptor Antagonists Phase 3
12 Estrogen Antagonists Phase 3
13 Protein Kinase Inhibitors Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
17
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
18
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
19
Tamoxifen Approved Phase 2 10540-29-1 2733526
20
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
21
Epirubicin Approved Phase 2 56420-45-2 41867
22
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
23
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
24 Tubulin Modulators Phase 2
25 Antimitotic Agents Phase 2
26 Albumin-Bound Paclitaxel Phase 2
27
Liposomal doxorubicin Phase 2 31703
28 Estrogen Receptor Modulators Phase 2
29 Aromatase Inhibitors Phase 2
30 Antibiotics, Antitubercular Phase 2
31 Immunologic Factors Phase 2
32 Immunosuppressive Agents Phase 2
33 Antirheumatic Agents Phase 2
34 Alkylating Agents Phase 2
35 Anti-Bacterial Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference? Unknown status NCT03111615 Phase 4 Aromatase Inhibitors
2 Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant® Recruiting NCT03447132 Phase 3 Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3 Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer Completed NCT01565499 Phase 2 Nab-paclitaxel
4 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
5 Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Recruiting NCT04023292 Phase 2 Endocrine therapy;Endocrine therapy
6 Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
7 Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients Recruiting NCT03370250
8 Identification and Monitoring of Resistance to First-line Treatment With CDK 4/6 Inhibitors in Combination With Aromatase Inhibitors in Patients With Metastatic Luminal Breast Cancer Through Non-invasive Biomarkers Recruiting NCT04660435

Search NIH Clinical Center for Luminal Breast Carcinoma a

Genetic Tests for Luminal Breast Carcinoma a

Anatomical Context for Luminal Breast Carcinoma a

MalaCards organs/tissues related to Luminal Breast Carcinoma a:

40
Breast

Publications for Luminal Breast Carcinoma a

Articles related to Luminal Breast Carcinoma a:

# Title Authors PMID Year
1
Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. 61
28739755 2017

Variations for Luminal Breast Carcinoma a

Cosmic variations for Luminal Breast Carcinoma a:

9 (show top 50) (show all 5031)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM137960127 ZNF598 breast,NS,carcinoma,ER-PR-positive carcinoma c.610G>A p.E204K 16:2002326-2002326 15
2 COSM135195220 ZNF598 breast,NS,carcinoma,ER-PR-positive carcinoma c.610G>A p.E204K 16:2002326-2002326 15
3 COSM99169942 YWHAQ breast,NS,carcinoma,ER-PR-positive carcinoma c.536A>G p.Y179C 2:9588211-9588211 15
4 COSM86351284 YWHAQ breast,NS,carcinoma,ER-PR-positive carcinoma c.536A>G p.Y179C 2:9588211-9588211 15
5 COSM143036457 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 15
6 COSM126968360 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.384G>A p.M128I 11:102206008-102206008 15
7 COSM127993455 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 15
8 COSM85231921 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 15
9 COSM133267649 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 15
10 COSM90942881 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 15
11 COSM145023383 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 15
12 COSM128447016 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 15
13 COSM105628484 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 15
14 COSM85917792 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 15
15 COSM142230116 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 15
16 COSM89270241 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 15
17 COSM85182140 WNT2 breast,NS,carcinoma,ER-PR-positive carcinoma c.321A>G p.E107= 7:117315338-117315338 15
18 COSM90882705 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 15
19 COSM128158629 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 15
20 COSM92018095 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 15
21 COSM130230128 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 15
22 COSM132341362 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 15
23 COSM88293154 VHL breast,NS,carcinoma,ER-positive carcinoma c.413C>T p.P138L 3:10146586-10146586 15
24 COSM90651104 VHL breast,NS,carcinoma,ER-positive carcinoma c.341-3273G>A p.? 3:10146514-10146514 15
25 COSM90653783 VHL breast,NS,carcinoma,ER-positive carcinoma c.341-3201C>T p.? 3:10146586-10146586 15
26 COSM88290785 VHL breast,NS,carcinoma,ER-positive carcinoma c.341G>A p.G114D 3:10146514-10146514 15
27 COSM140071241 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2103G>A p.K701= 19:6850739-6850739 15
28 COSM130163321 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2031G>A p.K677= 19:6850739-6850739 15
29 COSM141193936 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2034G>A p.K678= 19:6850739-6850739 15
30 COSM85972860 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2133G>A p.K711= 19:6850739-6850739 15
31 COSM142340805 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2199G>A p.K733= 19:6850739-6850739 15
32 COSM88837054 USP9X breast,NS,carcinoma,ER-PR-positive carcinoma c.3693A>T p.R1231S 23:41188000-41188000 15
33 COSM98536780 USP9X breast,NS,carcinoma,ER-PR-positive carcinoma c.3693A>T p.R1231S 23:41188000-41188000 15
34 COSM103478546 USP34 breast,NS,carcinoma,ER-PR-positive carcinoma c.4201C>A p.L1401I 2:61296853-61296853 15
35 COSM87092276 USP31 breast,NS,carcinoma,ER-PR-positive carcinoma c.721C>T p.H241Y 16:23108096-23108096 15
36 COSM93461611 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2344C>T p.P782S 21:29053952-29053952 15
37 COSM103742887 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2341C>T p.P781S 21:29053952-29053952 15
38 COSM103747829 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2344C>T p.P782S 21:29053952-29053952 15
39 COSM127063897 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4392C>G p.F1464L 8:102293802-102293802 15
40 COSM127538052 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4374C>G p.F1458L 8:102293802-102293802 15
41 COSM87429062 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4392C>G p.F1464L 8:102293802-102293802 15
42 COSM144361724 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
43 COSM101929825 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1872C>T p.Y624= 15:25356787-25356787 15
44 COSM149764169 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1863C>T p.Y621= 15:25356787-25356787 15
45 COSM108914927 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
46 COSM107120943 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
47 COSM145837560 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
48 COSM135842312 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
49 COSM85309324 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 15
50 COSM143810042 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1863C>T p.Y621= 15:25356787-25356787 15

Expression for Luminal Breast Carcinoma a

Search GEO for disease gene expression data for Luminal Breast Carcinoma a.

Pathways for Luminal Breast Carcinoma a

Pathways related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.66 HJURP H2BC14 CENPA
2 11.21 HJURP CENPA ASF1B

GO Terms for Luminal Breast Carcinoma a

Cellular components related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 MED7 MBD6 HJURP H2BC14 CHAF1B CENPA
2 nucleus GO:0005634 9.28 MED7 MED11 MBD6 HJURP H2BC14 ERBB2
3 mediator complex GO:0016592 9.26 MED7 MED11
4 chromosome GO:0005694 9.26 MBD6 HJURP H2BC14 CENPA

Biological processes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CENP-A containing nucleosome assembly GO:0034080 9.16 HJURP CENPA
2 DNA replication-dependent nucleosome assembly GO:0006335 8.96 CHAF1B ASF1B
3 nucleosome assembly GO:0006334 8.8 H2BC14 CHAF1B ASF1B

Molecular functions related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.33 MBD6 CHAF1B CENPA
2 protein heterodimerization activity GO:0046982 9.13 H2BC14 ERBB2 CENPA
3 histone binding GO:0042393 8.8 HJURP CHAF1B ASF1B

Sources for Luminal Breast Carcinoma a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....